Navigation Links
Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery
Date:8/27/2008

roviding the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis Pharmaceuticals Corporation researches, develops, manufactures and markets leading innovative prescription drugs used to treat a number of diseases and conditions, including those in the cardiovascular, metabolic, cancer, organ transplantation, central nervous system, dermatological, GI and respiratory areas. The company's mission is to improve people's lives by pioneering novel healthcare solutions.

Located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG (NYSE: NVS), which provides healthcare solutions that address the evolving needs of patients and societies. Focused on growth areas in healthcare, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, and consumer health products. Novartis is the only company with leading positions in these areas. In 2007, the Group's continuing operations (excluding divestments in 2007) achieved net sales of USD 38.1 billion and net income of USD 6.5 billion. Approximately USD 6.4 billion was invested in R&D activities throughout the Group. Headquartered in Basel, Switzerland, Novartis Group companies employ approximately 98,200 full-time associates and operate in over 140 countries around the world. For more information, please visit http://www.novartis.com.

For more information

Additional information regarding G
'/>"/>

SOURCE Novartis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia
2. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
3. Omaxe Infrastructure & Construction Private Ltd Receives LoI for Construction of Allopathic Medical College and Associated Hospital at Saharanpur, UP With Construction Value of Approx 250 Crores
4. Caliper Life Sciences Receives $1.1 Million Task Order from the EPAs ToxCast(TM) Screening Program
5. Biotest Diagnostics Receives FDA Clearance for Full Line of Traditional Blood Bank Reagents
6. BMP Sunstone Receives Production License from the SFDA to Manufacture and Market Pediatric Multivitamin Granules in the PRC
7. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
8. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
9. SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms
10. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
11. Medicsight Receives Brazilian State Food and Drug Administration Approval for ColonCAD Software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014 Philadelphia’s newest entrepreneurial incubation space is ... start. The Innovation Center @3401 , a collaborative effort ... Science Center to help attract and nurture start-up businesses ... 28. , The Innovation Center @3401 (ic@3401), ... Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)...  United Therapeutics Corporation (NASDAQ: ... for the second quarter ended June 30, 2014. ... our medicines are reaching increasing numbers of ... said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... this quarter of our extended-release tablet called ...
(Date:7/29/2014)... Dr. Jason Wendel – recipient of a ... of the Top 10 Plastic Surgeon Specialists for Nashville, TN ... His complete line includes a Hydration Booster, Retexturing Night Crème, ... and skin a younger, more radiant appearance while protecting them ... different, that is why at Dr. J. J. Wendel Plastic ...
(Date:7/28/2014)... , July 28, 2014 Sapphire ... technologies, today announced the appointment of biotechnology veteran ... the board of directors. Levine replaces Cynthia ,CJ, Warner, ... She will remain chairman of the company,s board of ... Sapphire Energy,s mission to deliver commercial scale algae-based fuels ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... , , Gene Provides Yield Stability During Periods of ... June 9, 2009 Monsanto Company (NYSE: MON ) ... help corn plants combat drought conditions and confer yield stability during ... stated that they will use the gene in their first-generation drought-tolerant ...
... Calif., June 9 STAAR Surgical Company (Nasdaq: ... of minimally invasive ophthalmic products, today announced that it ... Hydrophobic Acrylic Injector for use in minimally invasive cataract ... to market this foldable intraocular (IOL) KS-X lens delivery ...
... Collaborate on Testing OVAR Effectiveness , , PITTSBURGH, ... www.neuro-kinetics.com ), manufacturers of noninvasive medical evaluation equipment ... other disorders, said today that the University of ... Center has purchased and installed its I-Portal(R) NOTC (Neuro-Otologic ...
Cached Biology Technology:Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants 2Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants 3Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants 4Monsanto, BASF Scientists Disclose Discovery of Gene Conferring Drought Tolerance in Corn Plants 5STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 2STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 3STAAR Surgical Receives CE Mark Approval for KS-X Preloaded Hydrophobic Acrylic Lens Injector System 4University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 2University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 3
(Date:7/29/2014)... two of the major disciplines behind Jurassic Park is ... stunning photographs and unique illustrations. , Fossil Insects, by ... incredible preservation and diversity of fossilised insects from around ... fossils can tell us about the ancient and modern ... the mosquito in Jurassic Park, many of the hundreds ...
(Date:7/28/2014)... two additional coral communities showing signs of damage from the ... 2010 spill in the Gulf of Mexico. The discovery was ... biology at Penn State University. A paper describing this work ... Gulf of Mexico will be published during the last week ... journal Proceedings of the National Academy of Sciences . ...
(Date:7/28/2014)... CAMBRIDGE, MA -- Fifteen years ago, MIT professor John Essigmann ... idea for an HIV drug. They thought if they could ... to weaken and eventually die out a strategy that ... researchers developed such a drug, which caused HIV to mutate ... eliminate the virus from patients in a small clinical trial ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4
... most industrious workers now a study reveals why colonies of ... workers in social insect colonies such as ants, bees and ... instincts make them better at caring for the queen,s offspring. ... these highly organised insect societies. In these species, it is only ...
... Ruhr-Universitt Bochum (RUB) have developed a bio-based solar cell. ... which in plants are responsible of photosynthesis, into complex ... Headed by Prof Dr Wolfgang Schuhmann from the Department ... and Prof Dr Matthias Rgner from the Department of ...
... YORK, NY (November 21, 2013) In what is ... disease research, The New York Stem Cell Foundation (NYSCF) ... Health (NIH) Undiagnosed Disease Program (UDP). NYSCF scientists ... the UDP and collaborate with UDP researchers to better ...
Cached Biology News:Hardworking sisters enable insect colonies to thrive 2Bio-based solar cell 2NYSCF and NIH create cell models of rare and undiagnosed diseases 2NYSCF and NIH create cell models of rare and undiagnosed diseases 3
Adult Bovine Serum US Origin...
... 13(S)-HODE-d4 contains 4 deuterium atoms at the 9, ... for use as an internal standard for the ... 13(S)-HODE is produced by incubation of linoleic acid ... shown to inhibit the adhesion of tumor cells ...
...
...
Biology Products: